Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EBITDA (2022 - 2025)

Historic EBITDA for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$33.7 million.

  • Zentalis Pharmaceuticals' EBITDA rose 3441.05% to -$33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.3 million, marking a year-over-year increase of 2102.72%. This contributed to the annual value of -$191.2 million for FY2024, which is 3616.42% up from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its EBITDA stood at -$33.7 million for Q3 2025, which was up 3441.05% from -$36.1 million recorded in Q2 2025.
  • In the past 5 years, Zentalis Pharmaceuticals' EBITDA ranged from a high of -$24.8 million in Q1 2024 and a low of -$103.9 million during Q2 2023
  • Moreover, its 4-year median value for EBITDA was -$54.2 million (2022), whereas its average is -$55.6 million.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' EBITDA surged by 6187.24% in 2024, and later tumbled by 8422.37% in 2025.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' EBITDA stood at -$51.8 million in 2022, then crashed by 31.24% to -$67.9 million in 2023, then grew by 26.61% to -$49.8 million in 2024, then surged by 32.33% to -$33.7 million in 2025.
  • Its EBITDA was -$33.7 million in Q3 2025, compared to -$36.1 million in Q2 2025 and -$45.6 million in Q1 2025.